Cerity Partners
KYMR icon

Cerity Partners’s Kymera Therapeutics KYMR Stock Holding History

Cerity Partners’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$324K Sell
2,826
-1,555
-35% -$134K ﹤0.01% 2738
2026
Q1 		$365K Buy
+4,381
New +$347K ﹤0.01% 2479

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Cerity Partners's KYMR Position: Q2 2026 in Review

Cerity Partners reduced its Kymera Therapeutics (KYMR) stake by 35% in Q2 2026, selling an estimated $134K and leaving 2,826 shares worth $324K. The position accounts for ﹤0.01% of the portfolio, ranked #2738.

Cerity Partners first reported a position in KYMR in Q1 2026 and has held it in 2 quarters since. The position peaked at $365K in Q1 2026. 275 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

  • Cerity Partners held 2,826 shares of Kymera Therapeutics worth $324K as of Q2 2026.
  • Cerity Partners sold 1,555 Kymera Therapeutics shares in Q2 2026, an estimated $134K.
  • Kymera Therapeutics made up ﹤0.01% of Cerity Partners's portfolio in Q2 2026, its #2738 holding.
  • Cerity Partners first reported a position in Kymera Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Cerity Partners's Kymera Therapeutics position peaked at $365K in Q1 2026.
  • 275 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on Cerity Partners's 13F filing for Q2 2026, filed 14 Aug 2026.